These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32388886)

  • 1. Paradoxical plaque psoriasis due to secukinumab treatment in an ankylosing spondylitis patient.
    Durmaz K; Ataseven A; Ozer I
    Dermatol Ther; 2020 Jul; 33(4):e13504. PubMed ID: 32388886
    [No Abstract]   [Full Text] [Related]  

  • 2. Secukinumab can treat psoriasis induced by anti-TNF-alpha therapy in patients with ankylosing spondylitis: Case series.
    Apaydin H; Dogan I; Erten Ş
    Int J Rheum Dis; 2020 Mar; 23(3):454-456. PubMed ID: 31945270
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis: integrated pooled clinical trial and post-marketing surveillance data.
    Deodhar A; Mease PJ; McInnes IB; Baraliakos X; Reich K; Blauvelt A; Leonardi C; Porter B; Das Gupta A; Widmer A; Pricop L; Fox T
    Arthritis Res Ther; 2019 May; 21(1):111. PubMed ID: 31046809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New onset of psoriasis induced by secukinumab in a patient with ankylosing spondylitis: a case report.
    Currado D; Margiotta D; Conforti C; Coppola R; Panasiti V; Afeltra A; Navarini L
    Scand J Rheumatol; 2020 Jan; 49(1):75-76. PubMed ID: 31262212
    [No Abstract]   [Full Text] [Related]  

  • 5. Effects of guselkumab on ankylosing spondylitis-type pustulotic arthro-osteitis in a patient with palmoplantar pustulosis.
    Yamamoto T
    Dermatol Ther; 2020 Nov; 33(6):e14088. PubMed ID: 33439526
    [No Abstract]   [Full Text] [Related]  

  • 6. The risk of malignancy in patients with secukinumab-treated psoriasis, psoriatic arthritis and ankylosing spondylitis.
    van de Kerkhof PCM
    Br J Dermatol; 2021 Nov; 185(5):879. PubMed ID: 34402525
    [No Abstract]   [Full Text] [Related]  

  • 7. Combining secukinumab and fingolimod to successfully treat ankylosing spondylitis and multiple sclerosis - A novel approach.
    Nisar MK
    Biologicals; 2019 Jul; 60():93-94. PubMed ID: 31204079
    [No Abstract]   [Full Text] [Related]  

  • 8. Persistence of secukinumab in patients with psoriasis, psoriatic arthritis, and ankylosing spondylitis.
    Conesa-Nicolás E; García-Lagunar MH; Núñez-Bracamonte S; García-Simón MS; Mira-Sirvent MC
    Farm Hosp; 2020 Dec; 45(1):16-21. PubMed ID: 33443473
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating to Target(s) With Interleukin-17 Inhibitors.
    Lynde CW; Beecker J; Dutz J; Flanagan C; Guenther LC; Gulliver W; Papp K; Rahman P; Sholter D; Searles GE
    J Cutan Med Surg; 2019; 23(2_suppl):3S-34S. PubMed ID: 30742778
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secukinumab may be a valid treatment option in patients with CNS demyelination and concurrent ankylosing spondylitis: Report of two clinical cases.
    Cortese A; Lucchetti R; Altobelli A; Conte A; Primavera M; Valesini G; Millefiorini E; Scrivo R
    Mult Scler Relat Disord; 2019 Oct; 35():193-195. PubMed ID: 31398658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammatory bowel disease new-onset during secukinumab therapy: real-world data from a tertiary center.
    Ojeda Gómez A; Madero Velázquez L; Buendía Sanchez L; Pascual Sánchez I; Pérez Rabasco E; García Monsalve A; González Ferrández JA; García Sepulcre MF
    Rev Esp Enferm Dig; 2021 Dec; 113(12):858-859. PubMed ID: 34696593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-17 for therapy.
    Kurschus FC; Moos S
    J Dermatol Sci; 2017 Sep; 87(3):221-227. PubMed ID: 28633806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Fonti GL; Chimenti MS; Greco E; Boffa L; Conigliaro P; Triggianese P; Perricone R
    Clin Exp Rheumatol; 2021; 39(1):223. PubMed ID: 32452349
    [No Abstract]   [Full Text] [Related]  

  • 14. Reply to: Safety and efficacy of secukinumab treatment in a patient with ankylosing spondylitis and concomitant multiple sclerosis: a commentary.
    Macaluso F; Guggino G; Ciccia F
    Clin Exp Rheumatol; 2021; 39(1):224. PubMed ID: 32452343
    [No Abstract]   [Full Text] [Related]  

  • 15. Real-world experience of secukinumab treatment for ankylosing spondylitis at the Royal National Hospital for Rheumatic Diseases, Bath.
    Williams T; Wadeley A; Bond D; Cavill C; Freeth M; Sengupta R
    Clin Rheumatol; 2020 May; 39(5):1501-1504. PubMed ID: 31989323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database.
    Warren RB; Reich K; Langley RG; Strober B; Gladman D; Deodhar A; Bachhuber T; Bao W; Altemeyer E; Hussain S; Safi J
    Br J Dermatol; 2018 Nov; 179(5):1205-1207. PubMed ID: 29927479
    [No Abstract]   [Full Text] [Related]  

  • 17. Secukinumab: first global approval.
    Sanford M; McKeage K
    Drugs; 2015 Feb; 75(3):329-38. PubMed ID: 25648267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost per responder analysis of secukinumab vs adalimumab for the treatment of ankylosing spondylitis from the Korean perspective.
    Kim D; Kim H; Cho S; Park MC
    Int J Rheum Dis; 2019 Sep; 22(9):1630-1637. PubMed ID: 31215166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of secukinumab in Japanese patients with active ankylosing spondylitis: 24-week results from an open-label phase 3 study (MEASURE 2-J).
    Kishimoto M; Taniguchi A; Fujishige A; Kaneko S; Haemmerle S; Porter BO; Kobayashi S
    Mod Rheumatol; 2020 Jan; 30(1):132-140. PubMed ID: 30334633
    [No Abstract]   [Full Text] [Related]  

  • 20. Secukinumab treatment of tumor necrosis factor antagonists induced paradoxical psoriasis flares in a patient with plaque psoriasis.
    Zheng J; Li Y; Ding Y; Gao Y
    Dermatol Ther; 2020 Nov; 33(6):e14455. PubMed ID: 33107149
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.